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Microvolt T-Wave Alternans:
Where Do We Go From Here?
The recent meta-analysis by Gehi et al. (1) assessed the value of
microvolt T-wave alternans (MTWA) testing to predict cardiac
arrhythmic events in differing patient populations. Their analyses
provide a summary estimate of the predictive value of MTWA in
patients with ischemic and non-ischemic cardiomyopathy. In their
discussion, the investigators point out that while MTWA has
shown promise in identifying high-risk patients, studies have been
hampered by small sample sizes. Importantly, this has limited the
comparisons of baseline characteristics between individuals with
negative and non-negative MTWA tests in most studies and has
prevented adequate multivariable adjustment for potential con-
founders.
This raises questions as to whether MTWA is simply a
surrogate marker of patients with greater disease burden and
severity. If so, differences in age, left ventricular ejection fraction
(LVEF), clinical comorbidities, and medication treatment between
individuals with negative and non-negative MTWA tests may
explain its predictive power. We believe that in order for MTWA
to gain wider acceptance as a risk stratification tool, three types of
analyses are needed. First, multivariable modeling that adjusts for
demographics, LVEF, clinical comorbidities, medication treatment,
as well as electrophysiologic variables (e.g., Holter monitoring, QRS
duration, electrophysiologic study) should be done to show that
MTWA is an independent predictor of cardiac arrhythmias. Gehi et al.
(1) themselves acknowledge that MTWA does not offer incremental
prognostic utility unless it can be shown to add predictive power
beyond known risk factors for cardiac arrhythmia (such as LVEF in
patients with ischemic cardiomyopathy).
Second, studies of MTWA should provide analyses of
all-cause mortality in addition to arrhythmic mortality. Prior
studies of MTWA that used a primary end point of cardiac
arrhythmic events may be limited as they did not consider
competing risks whereby MTWA may predict arrhythmic, but
not all-cause, mortality.
Finally, even if future studies demonstrate that MTWA offers
incremental prognostic utility in assessing high-risk patients, its
true utility for risk stratification will only be known when the
mortality reduction benefit of implantable cardioverter-defibrillators
(ICDs) is evaluated in patients who test MTWA-negative and
non-negative. This could be accomplished by randomizing patients to
ICD therapy after MTWA testing, but such a clinical trial might
raise ethical concerns given that some high-risk patients may be
denied life-saving therapy. To justify such a clinical trial, additional
cohort analysis using propensity scores for ICD therapy based on
MTWA status may be needed (2).
Gehi et al. (1) are to be commended for their synthesis of a large
pool of clinical data on MTWA. Future studies of MTWA should
focus on its incremental prognostic utility after multivariable
adjustment, but ultimately the true utility of MTWA in risk-
stratifying high-risk patients will remain uncertain unless it can be
shown that the benefit of ICDs differs by MTWA subgroup.
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REPLY
We appreciate the thoughtful comments of Dr. Chan and col-
leagues regarding our meta-analysis of microvolt T-wave alternans
(MTWA) and wish to expand upon several points (1).
As dicussed by Dr. Chan and colleagues and as we pointed out
in our Discussion section, very few studies have demonstrated
whether MTWA is predictive of future arrhythmic events inde-
pendent of other well-established clinical predictors. There is
substantial evidence regarding the prognostic utility of other risk
predictors, including ejection fraction (EF), signal-averaged elec-
trocardiogram (ECG), heart rate variability, electrophysiologic
study, and baroreflex sensitivity. Though MTWA may be the test
currently in vogue, until MTWA is shown to add substantial
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